We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A bellwether trial jury in Louisiana cleared Sanofi of liability over claims that it failed to issue adequate warnings that its chemotherapy drug Taxotere (docetaxel anhydrous) could cause permanent hair loss. Read More
In a first for the agencies, the FDA and the Drug Enforcement Administration issued joint warning letters to four website operators for illegally selling opioids. Read More
The European Medicines Agency has ordered drug companies to review their products within the next six months for contamination with nitrosamines. Read More
The FDA’s Office of Prescription Drug Promotion (OPDP) sent a warning letter to Galt Pharmaceuticals for intentionally sending an email to doctors about its insomnia pill Doral (quazepam) that left out the fact that the drug is a benzodiazepine, a class-four controlled substance. Read More
Johnson & Johnson and its Janssen subsidiary appealed Oklahoma’s $572 million opioid court verdict to the state’s Supreme Court, arguing they were unjustly singled out as responsible for the opioid crisis. Read More